financetom
Business
financetom
/
Business
/
--PACCAR Keeps Quarterly Dividend at $0.30 Per Share; Payable Sept. 5 to Shareholders of Record on Aug. 15
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--PACCAR Keeps Quarterly Dividend at $0.30 Per Share; Payable Sept. 5 to Shareholders of Record on Aug. 15
Jul 9, 2024 6:57 AM

09:37 AM EDT, 07/09/2024 (MT Newswires) --

Price: 101.36, Change: +0.08, Percent Change: +0.08

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Exxon's deal with unions at Port Jerome refinery to allow job-cutting plan to move ahead
Exxon's deal with unions at Port Jerome refinery to allow job-cutting plan to move ahead
Oct 3, 2024
(Reuters) - Energy major Exxon Mobil ( XOM ) can move ahead with a plan to cut jobs at its Port Jerome refinery in northern France after obtaining a majority agreement this week with unions, a company spokesperson said on Thursday. Workers at the petrochemical side of the refinery have been on strike since mid-May to try to safeguard jobs...
Levi Strauss shares fall on sluggish holiday quarter forecast
Levi Strauss shares fall on sluggish holiday quarter forecast
Oct 3, 2024
(Reuters) - Levi Strauss' shares slumped about 11% in premarket trading on Thursday after it forecast tepid holiday quarter revenue as the denim maker grapples with weak demand from retailers with consumers paring back spending. The company, whose stock has risen about 27% so far this year and was trading at $18.77 premarket, also said on Wednesday it was considering...
Elevai Labs Unit Seeks Patents for Lead Drug Candidate to Treat Muscle Loss in Obese Patients
Elevai Labs Unit Seeks Patents for Lead Drug Candidate to Treat Muscle Loss in Obese Patients
Oct 3, 2024
08:17 AM EDT, 10/03/2024 (MT Newswires) -- Elevai Labs ( ELAB ) said Thursday that its Elevai Biosciences subsidiary filed two patent applications for its lead candidate, EL-22, to treat muscle loss in obese patients. The applications cover both standalone and combination therapies with GLP-1 receptor agonists, according to the company. A phase 1 study of EL-22 in South Korea...
Legend Biotech to Open New Cell Therapy R&D Facility in Philadelphia
Legend Biotech to Open New Cell Therapy R&D Facility in Philadelphia
Oct 3, 2024
08:19 AM EDT, 10/03/2024 (MT Newswires) -- Legend Biotech ( LEGN ) said Thursday it is constructing a new research and development site in Philadelphia, Pennsylvania for advancing its cell therapies portfolio. The company anticipates to complete the development in Q3 2025. The new facility is expected to have 55 full-time employees, the company said. Price: 48.41, Change: -0.27, Percent...
Copyright 2023-2026 - www.financetom.com All Rights Reserved